NASDAQ$ZYME
Zymeworks Inc · Q4 2025 earnings
Q4 2025 earnings · · Before market open · Investor relations
Briefing
ZYME reported Q4 2025, revenue of $106M, a net loss of $81.1M.
For Q4 2025, ZYME reported revenue of $106M, a net loss of $81.1M. Management discusses segment performance, capital allocation, and macro risks in the quarterly filing.
- Revenue $106M.
- Net loss $81.1M.
- ZYME MD&A covers liquidity, operating priorities, and sector risks.
Headline financials
Revenue & EPS history
Zymeworks · Revenue · Quarterly
$106M
Forward guidance
The quarterly filing discusses operating priorities, capital returns, and sector risks.
Tailwinds
- MD&A highlights liquidity and core business trends.
- Segment commentary supports the earnings narrative.
Headwinds
- Macro or input-cost pressure may affect margins.
- One-time items can affect YoY comparability.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 13 quarterly earnings reports · overlaid with Q4 2025
-1.2%
Avg return
Earnings day
-0.4%
Avg return
5 days after
+7.6%
Avg return
30 days after
38%
5 / 13 earnings
Positive
+1.4%
Q1 2023
Best reaction
-8.0%
Q3 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -3.6% | -13.5% | -13.0% | |
| Q4 2025 | +0.1% | +3.4% | +11.4% | |
| Q3 2025 | -8.0% | +8.2% | +49.1% | |
| Q1 2025 | -0.1% | -0.6% | +11.3% | |
| Q4 2024 | -8.0% | -11.2% | -16.9% | |
| Q3 2024 | +1.0% | +1.2% | +11.7% | |
| Q2 2024 | +0.0% | +4.3% | +22.4% | |
| Q1 2024 | +0.0% | -8.3% | -18.4% | |
| Q4 2023 | +0.0% | +1.6% | +3.8% | |
| Q3 2023 | +1.2% | +0.1% | +31.2% | |
| Q3 2021 | +0.0% | -1.3% | +10.3% | |
| Q2 2023 | +0.8% | -3.6% | -7.5% | |
| Q1 2023 | +1.4% | +14.1% | +2.9% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro